Applied Therapeutics Inc (APLT) 銘柄情報

Got a double now, so I sold 25%
Will sell the rest at $1.50 for a five bagger with the rest.
Chers!

APLT......................................https://stockcharts.com/h-sc/ui?s=APLT&p=W&b=5&g=0&id=p86431144783

Poor shorts are starting to get rather nervous.
But this is only the beginning. See you above $1 soon!😁

Oops.....starting to move up a little more, shall we say, vigorously
😁

Shorts Will provide the rocket fuel when they begin covering, as usual.
😃

In with a boatload and at an average of .312.
Double any day from here.
Tick tock......

Gotcha…

Better opportunity elsewhere

Are you in too TT? Shhh….

Happy Saturday Monk! Would you be long a thus point? .55?

Get in for a DOUBLE+!

It will happen as soon as they present their data to the FDA during this quarter (any day now).

YES

DESPERATE manipulation going on courtesy of the ambulance chasers. 

Double coming soon - maybe much more. LOL

$APLT$

APLT.................................https://stockcharts.com/h-sc/ui?s=APLT&p=W&b=5&g=0&id=p86431144783

Easy DOUBLE coming up here soon.

$APLT$

YES

APLT..............................................https://stockcharts.com/h-sc/ui?s=APLT&p=W&b=5&g=0&id=p86431144783

Added 3000 today at .5407.

$APLT$

And what will happen with all the frivolous lawsuits?

When the price triples in one day from here, the stock will continue to recover, moving higher and higher until the lawsuits, along with our ambulance chaser friends will look like bafoons.

YES

$APLT$

APLT's strategy is to present to the FDA  in Q1 of 2025 their results Galactosemia, SORD Deficiency, and PMM2-CDG. The company is also developing AT-001 for Diabetic Cardiomyopathy and Diabetic Peripheral Neuropathy, and AT-003 for Diabetic Retinopathy, addressing significant unmet needs in diabetes care.


If ANY of these results have ANY success, we are looking at a four bagger in a single day from these levels.


The risk/reward is highly attractive.

Short covering has officially begun. 😁

It's up from here. Maybe a few shenanigans are still in store, but it's up from here.

Would not be surprised to see a double suddenly on a volume spike. Just look at the time and sales from last Friday.

About 5 million shares were bought in the last 5 minutes of trading. Somebody knows something.

Was this the bottom?

Jumped in with a starter at .64

Any halfway decent news will spike this IMHO.

The company has been totally "crickets" since the debacle of some weeks ago.

But truth be told, a decent PR from theses folks could send this spiking to the upside.

All you need is a few cojones. lol😅

APLT...................https://stockcharts.com/h-sc/ui?s=APLT&p=W&b=5&g=0&id=p86431144783

aplt.............................................https://stockcharts.com/h-sc/ui?&s=aplt&id=p80904663129&listNum=4&a=1431976465

What is the Lawsuit About?

Applied Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of novel drug candidates against validated molecular targets in rare diseases. The Company's lead drug candidate, govorestat, is a central nervous system penetrant Aldose Reductase Inhibitor for the treatment of CNS rare metabolic diseases, including Galactosemia.

During the relevant period, the Company stated that its New Drug Applications submitted to regulators for govorestat were“supported by rapid and sustained reduction in galactitol, which resulted in a meaningful benefit on clinical outcomes across pediatric patients, alongside a favorable safety profile.” Applied Therapeutics also assured investors that its tests were“performed properly” and that the Company“felt good about the quality of the data,” stating that it“took really extensive steps” and“actually videotaped” and had“master trainers” review all of the performances of the 10-meter walk-run test-the primary endpoint of the Company's Phase III INSPIRE study for govorestat.

The Stock Declines as the Truth is Revealed
On November 27, 2024, Applied Therapeutics issued a press release stating that the FDA issued a Complete Response Letter for the NDA for govorestat. The Complete Response Letter stated that the FDA completed its review of the application and determined that it was unable to approve the NDA due to“deficiencies in the clinical application.”

This news caused the price of Applied Therapeutics stock to fall more than 80% over the course of multiple trading days, from a closing price of $10.21 per share on November 26, 2024 to a closing price of $1.75 per share on December 2, 2024.

Then, on December 2, 2024, Applied Therapeutics revealed that it received a warning letter from the FDA relating to its govorestat study discussing“issues related to electronic data capture” and“a dosing error in the dose-escalation phase of the study resulting in slightly lower levels than targeted in a limited number of patients[.]”

This news caused the price of Applied Therapeutics stock to fall more than 26% over the course of multiple trading days, from a closing price of $1.75 per share on December 2, 2024 to a closing price of $1.29 per share on December 5, 2024.

Click here for more information: .

What Can You Do?

If you invested in Applied Therapeutics you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:


Or contact:
Ross Shikowitz
...
212-789-3619

Why Bleichmar Fonti & Auld LLP?

Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs' Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.'s Board of Directors (pending court approval), as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit .


Attorney advertising. Past results do not guarantee future outcomes.




MENAFN01012025004107003653ID1109046768


GlobeNewsWire - Nasdaq
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.


Tags

Label
Comments

No comment
Category


Date

1/1/2025

Most popular stories
Poland Assumes EU Council Presidency With Focus On Security...
Poland Assumes EU Council Presidency With Focus On Security...
When Will Rigetti And These Two Stock Rally End?...
When Will Rigetti And These Two Stock Rally End?...
Dubai: Is It Time To Shift From Gold To Diamonds? Changing Jewellery T...
Dubai: Is It Time To Shift From Gold To Diamonds? Changing Jewellery T...
Dubai: Gold Prices Jump In Early Trade On New Year, Set To Stay High I...
Dubai: Gold Prices Jump In Early Trade On New Year, Set To Stay High I...
'Bruce Lee Of Afghanistan' Dreams Visting Hong Kong, Performing In Mov...
'Bruce Lee Of Afghanistan' Dreams Visting Hong Kong, Performing In Mov...
M&M 11Th Most Valuable Automobile Manufacturer In World: Anand Mahindr...
M&M 11Th Most Valuable Automobile Manufacturer In World: Anand Mahindr...

Market Research
Market Research

Manuka Honey Market Report 2024, Industry Growth, Size, Share, Top Compan...
Modular Kitchen Market 2024, Industry Growth, Share, Size, Key Players An...
Acrylamide Production Cost Analysis Report: A Comprehensive Assessment Of...
Fish Sauce Market 2024, Industry Trends, Growth, Demand And Analysis Repo...
Australia Foreign Exchange Market Size, Growth, Industry Demand And Forec...
Cold Pressed Oil Market Trends 2024, Leading Companies Share, Size And Fo...
Pasta Sauce Market 2024, Industry Growth, Share, Size, Key Players Analys...

APLT on the move here.

I see a great opportunity here at these levels. That price drop was quite exaggerated.

Option trade today 1/17/25, $12.50 @1,000

Option trade today 1/17/25, $12.50 @1,000

APLT: 200%-up, for sure today.

Applied Therapeutics Provides Regulatory Update on Govorestat for the Treatment of Classic Galactosemia

APLT under $7

APLT under $5

I have held this for several years and there are many prospects progressing. I like the significant CEO ownership position.

APLT new 52 week high

APLT new 52 week high

Outstanding

Applied Therapeutics Announces $100 Million Private Placement

OMG.. really..

yup.. my mistake that i overlooked you.. you will financial crisis for the next 3 years..

APLT what a beast and not one ihubber talking. The best kind!

APLT...NEXT MONSTER BIO BEAST!!!

APLT...HUGE BREAK OUT PLAY

APLT..THE NEXT BIO BEAST THAT WILL BEAST THROUGH BEASTVILLE

APLT...4.47 HERE WE COME

APLT...ANOTHER MONSTER IN THE MAKING

APLT..HERE WE GO

APLT STRONG TREND IN PLACE

Maybe this could run back up to where it was 4 years ago.